View : 216 Download: 0
Current perspectives on therapeutic antibodies
- Current perspectives on therapeutic antibodies
- Yoon S.; Kim Y.-S.; Shim H.; Chung J.
- Ewha Authors
- SCOPUS Author ID
- Issue Date
- Journal Title
- Biotechnology and Bioprocess Engineering
- Biotechnology and Bioprocess Engineering vol. 15, no. 5, pp. 709 - 715
- SCIE; SCOPUS; KCI
- Document Type
- Since the first monoclonal antibody, muromonab-CD3, was approved for therapeutic use in 1986, numerous molecules have been targeted using therapeutic antibody technology, resulting in 26 therapeutic antibodies being approved by the US FDA as of November, 2009. Initial concerns regarding antibody drugs focused on immunogenicity, short serum half-life, and weak efficacy. As the types of antibodies progressed from murine to chimeric, humanized, and fully human antibodies, great progress has been made in immunogenicity and in vivo instability issues. For example, humanized antibodies, such as bevacizumab, exhibit less than 0.2% immunogenicity and a 20 day serum half-life, which is comparable to native immunoglobulin. Some recently developed antibodies are exceedingly efficacious and have become first-line therapy for their target diseases. Here, we address and analyze all clinically approved therapeutic antibodies to date by discussing immunogenicity, half-life, and efficacy. © 2010 The Korean Society for Biotechnology and Bioengineering and Springer-Verlag Berlin Heidelberg.
- Appears in Collections:
- 일반대학원 > 바이오융합과학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.